Sirt1 activated mitochondrial biogenesis, and together with pAMPK inhibited PPARγ/SCREBP-1c induced FAS activity and TG levels to alleviate the NAFLD (Figure 9). Here, FAS is linked to metabolic dysfunction-associated steatotic liver disease.